PURPOSE: Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (PPH) are poorly understood pulmonary complications of end-stage liver disease (ESLD). We present a case series of children with HPS and PPH. METHODS: After institutional review board approval, query of our medical database identified children 0 to 18 years of age with ESLD diagnosed with HPS or PPH. Data were collected via chart review. RESULTS: We identified 7 children with either HPS (n = 5) or PPH (n = 2). Patients with HPS presented with progressive dyspnea over a mean of 7 months (range, 4-12 months) at a mean of 13 years (range, 5-17 years) of age. Pulmonary shunting by albumin perfusion scan averaged 41% (range, 20%-66%) with an initial mean resting SpO(2) of 88% (range, 84%-94%) and mean SpO(2) during exertion of 79% (range, 60%-89%). Four patients required supplemental O(2) and, upon United Network for Organ Sharing (UNOS) appeal, received pediatric model for ESLD (or Child-Pugh) score exceptions, enabling them to undergo orthotopic liver transplant (OLT) within 1-2 months. The fifth patient was initially rejected by the UNOS regional review board, but 6 months of worsening hypoxemia led to OLT 2 months after successful UNOS appeal. All patients with HPS undergoing OLT experienced complete resolution of hypoxemia within 8 months. Both children with PPH were treated with intravenous epoprostenol, which lowered or stabilized mean pulmonary artery pressure and bridged them to OLT within 7 months of listing. Overall, there were no pulmonary complications; however, 1 patient with PPH expired shortly after OLT. The remaining patients are alive at a median follow-up of 27 months (range, 6-96 months). CONCLUSION: Hepatopulmonary syndrome and PPH are uncommon complications of ESLD in children. Epoprostenol can bridge PPH patients to OLT. OLT leads to rapid resolution of HPS and PPH and currently represents the only successful treatment for these children.
PURPOSE:Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (PPH) are poorly understood pulmonary complications of end-stage liver disease (ESLD). We present a case series of children with HPS and PPH. METHODS: After institutional review board approval, query of our medical database identified children 0 to 18 years of age with ESLD diagnosed with HPS or PPH. Data were collected via chart review. RESULTS: We identified 7 children with either HPS (n = 5) or PPH (n = 2). Patients with HPS presented with progressive dyspnea over a mean of 7 months (range, 4-12 months) at a mean of 13 years (range, 5-17 years) of age. Pulmonary shunting by albumin perfusion scan averaged 41% (range, 20%-66%) with an initial mean resting SpO(2) of 88% (range, 84%-94%) and mean SpO(2) during exertion of 79% (range, 60%-89%). Four patients required supplemental O(2) and, upon United Network for Organ Sharing (UNOS) appeal, received pediatric model for ESLD (or Child-Pugh) score exceptions, enabling them to undergo orthotopic liver transplant (OLT) within 1-2 months. The fifth patient was initially rejected by the UNOS regional review board, but 6 months of worsening hypoxemia led to OLT 2 months after successful UNOS appeal. All patients with HPS undergoing OLT experienced complete resolution of hypoxemia within 8 months. Both children with PPH were treated with intravenous epoprostenol, which lowered or stabilized mean pulmonary artery pressure and bridged them to OLT within 7 months of listing. Overall, there were no pulmonary complications; however, 1 patient with PPH expired shortly after OLT. The remaining patients are alive at a median follow-up of 27 months (range, 6-96 months). CONCLUSION:Hepatopulmonary syndrome and PPH are uncommon complications of ESLD in children. Epoprostenol can bridge PPHpatients to OLT. OLT leads to rapid resolution of HPS and PPH and currently represents the only successful treatment for these children.
Authors: Amany I Gorgy; Naudia L Jonassaint; Susan E Stanley; Ayman Koteish; Amy E DeZern; Jolan E Walter; Sabrina C Sopha; James P Hamilton; Julie Hoover-Fong; Allen R Chen; Robert A Anders; Ihab R Kamel; Mary Armanios Journal: Chest Date: 2015-10 Impact factor: 9.410
Authors: Erin Neil; Josef Cortez; Aparna Joshi; Erawati V Bawle; Janet Poulik; Mark Zilberman; Mohammad F El-Baba; Beena G Sood Journal: Ital J Pediatr Date: 2010-05-18 Impact factor: 2.638
Authors: Ali Nawaz Khan; Hamdan Al-Jahdali; Khalid Abdullah; Klaus L Irion; Quratulain Sabih; Alaa Gouda Journal: Ann Thorac Med Date: 2011-04 Impact factor: 2.219
Authors: Maria Jesus Del Cerro; Steven Abman; Gabriel Diaz; Alexandra Heath Freudenthal; Franz Freudenthal; S Harikrishnan; Sheila G Haworth; Dunbar Ivy; Antonio A Lopes; J Usha Raj; Julio Sandoval; Kurt Stenmark; Ian Adatia Journal: Pulm Circ Date: 2011 Impact factor: 3.017
Authors: Bingsong Huang; Yi Shi; Jun Liu; Paul M Schroder; Suxiong Deng; Maogen Chen; Jun Li; Yi Ma; Ronghai Deng Journal: BMC Gastroenterol Date: 2018-06-07 Impact factor: 3.067